Just In
- 41 min ago Mahavir Jayanti 2024: Date, Time, History, Celebrations And Teachings Of Lord Mahavir In Jainism
- 1 hr ago Parineeti Chopra Saree Looks: Check Amar Singh Chamkila Actor's Regal Fashion Statements
- 3 hrs ago Vidya Balan's 'Do Aur Do Pyaar' Urban Boho Style Avatar Is Relatable And Inspiring, Check Her Modern Avatar!
- 11 hrs ago Golden Rules To Follow For Happy Marriage For A Long Lasting Relationship
Don't Miss
- Movies Devara Part 1: Jr NTR To Groove With Pooja Hegde In Janhvi Kapoor-Starrer Actioner For A Special Song; Details
- Sports ONE Friday Fights 59 Results: Yamin Beats Ouraghi In Freak Stoppage, Yodthongthai Topples Petnamngam
- News Bengaluru Traffic Alert: Avoid These Roads On April 20 Between 1 PM To 7 PM
- Automobiles Ford Mustang 60th Anniversary Package – Limited To Just 1,965 Units
- Technology Confirmed List of Products Launching at Xiaomi Smarter Living 2024
- Finance Daily Relative Strength Index RSI In A Bullish Mode of This Pharma Stock; Buy For TP Rs 635-685
- Education Exam Pressure Does Not Exist; Studying Punctually is Crucial; Says Aditi, the PSEB 2024 Topper
- Travel Journey From Delhi To Ooty: Top Transport Options And Attractions
Covaxin Has Cellular Immune Memory To COVID For At Least 6 Months: National Institute Of Immunology
Bharat Biotech's Covaxin has immunological memory to Covid and its variants of concern for at least up to six months, National Institute of Immunology (NII) director in-charge Pushkar Sharma said on Monday. It means the vaccine can provide protection from the virus for a minimum of that duration.
Immunological memory is the ability of the immune system to respond more rapidly and effectively to pathogens that have been encountered previously.
"The inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern- Delta, Alpha, Beta and Gamma, which persist at least up to 6 months," Sharma said during the annual general body meeting of the society of NII.
The meeting, held on Sunday, was presided over by Union Minister for Science and Technology Jitendra Singh. Sharma presented the work done by the institution in understanding fundamental processes that regulate inflammation, pathogenesis, ageing and immune response, the Science and Technology Ministry said in a statement.
He mentioned that the focus has been on various areas of research, including infection and immunity, molecular design, gene regulation and reproduction and development. In these areas, cutting edge research in modern biology is being carried out employing multiple overlapping disciplines of modern biology. He mentioned that significant efforts have been made towards transitional research specifically for the SARS-CoV-2 vaccine.
NII has also provided services for COVID-19 research. Under this programme, 65 Medical laboratory technologists (MLTs)/lab technicians were trained in various aspects of COVID-19. There have been more than 30,000 samples screened so far and the positive samples have been sent for genome sequencing.
Sharma further elaborated that NII has also developed a collagen-based herbal formulation for osteoarthritis (OA). The formulation (SG002) contains a bioactive collagen peptide and alcoholic extract of two exotic Himalayan plants. He added that the institute is also part of the Indo-European Consortium for Next Generation Influenza Vaccination.
The institution is part of the group working on the COBRA (Computationally Optimized Broadly Reactive Antigen) vaccine.
It will be developed by analysing the sequence of influenza strains over a decade covering seasonal and pandemic strains. Based on the research from the last two decades it is suggested that the COBRA vaccine is expected to provide protection against seasonal flu, all the pandemic strains of flu and any emerging flu strains, the statement said.
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- wellnessCorbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
- kidsCovid-19 Vaccines For Kids: DCGI Grants Emergency Use Nod To 3 Vaccines For Different Age Group Of Children
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- wellnessIndia's Covaxin To Be Evaluated As COVID-19 Vaccine Candidate In USA
- healthCovaxin Granted Emergency Use Listing In 13 Nations As On Jan 31 According To WHO: Government
- healthEach Dose Of Covishield, Covaxin Likely To Be Capped At Rs 275 After Getting Regular Market Approval
- healthMedia Reports Stating Vaccine Shortage In Maharashtra Are Not Factually Correct: Govt
- healthGovt's Decision On COVID-19 Vaccination For Children 'Unscientific': Senior AIIMS Epidemiologist
- healthCovaxin's Shelf Life Extended To 12 Months From Date Of Manufacture
- healthExperts Allay Covaxin Concerns, Say 50% Effectiveness Against Delta-Driven COVID-19 Surge Not Bad
- healthGovernment Nod To Commercial Export Of Covishield, Covaxin In View Of Sufficient Stock